Medigen Vaccine Biologics (ROCO:6547) Pretax Margin %: -93.99% (As of Dec. 2025)


ROCO:6547 Medigen Vaccine Biologics Corp ROCO:6547
67 GF Score
Price NT$46.35
GF Value NT$70.01
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Medigen Vaccine Biologics Pretax Margin %?

Medigen Vaccine Biologics ROCO:6547 +2.09% 67 Pretax Margin % is -93.99% as of Dec. 2025. GuruFocus rates ROCO:6547 with a GF Score™ of 67/100 and a GF Value™ of NT$70.01 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Medigen Vaccine Biologics ranks better than 56.6% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Medigen Vaccine Biologics's Pre-Tax Income for the three months ended in Dec. 2025 was NT$-138.2 Mil. Medigen Vaccine Biologics's Revenue for the three months ended in Dec. 2025 was NT$147.0 Mil. Therefore, Medigen Vaccine Biologics's pretax margin for the quarter that ended in Dec. 2025 was -93.99%.

The historical rank and industry rank for Medigen Vaccine Biologics's Pretax Margin % or its related term are showing as below:

ROCO:6547' s Pretax Margin % Range Over the Past 10 Years
Min: -55153.39   Med: -297.68   Max: 42.98
Current: -45.94


ROCO:6547's Pretax Margin % is ranked better than
56.6% of 940 companies
in the Biotechnology industry
Industry Median: -89.895 vs ROCO:6547: -45.94

Medigen Vaccine Biologics  (ROCO:6547) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Medigen Vaccine Biologics Pretax Margin % Related Terms


Medigen Vaccine Biologics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Medigen Vaccine Biologics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Vaccine Biologics Pretax Margin % Chart

Medigen Vaccine Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.98 -403.95 -297.68 -13.29 -45.94

Medigen Vaccine Biologics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.17 -18.23 -68.95 -10.98 -93.99

ROCO:6547 vs VRTX, REGN, ALNY: Pretax Margin % Comparison

For the Biotechnology subindustry, Medigen Vaccine Biologics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Vaccine Biologics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Medigen Vaccine Biologics's Pretax Margin % falls into.


ROCO:6547
67GF Score
Medigen Vaccine Biologics Corp ROCO:6547
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Vaccine Biologics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Medigen Vaccine Biologics's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-281.714/613.171
=-45.94 %

Medigen Vaccine Biologics's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-138.184/147.013
=-93.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -93.99% mean?
Medigen Vaccine Biologics (ROCO:6547) has a Pretax Margin % of -93.99% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Medigen Vaccine Biologics and its competitors. According to the industry distribution chart, Medigen Vaccine Biologics ranks #408 out of 940 companies in the Biotechnology industry, placing it in the top 43.4%.
Is Medigen Vaccine Biologics' Pretax Margin % too high?
Medigen Vaccine Biologics' current Pretax Margin % is -93.99%. Based on the distribution chart, Medigen Vaccine Biologics ranks #408 out of 940 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medigen Vaccine Biologics has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #408 out of 940 companies for Pretax Margin %. This puts Medigen Vaccine Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Medigen Vaccine Biologics and its competitors. Medigen Vaccine Biologics's current Pretax Margin % is -93.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.01, compared to a current price of NT$46.35 — trading 33.8% below its estimated fair value. The current Pretax Margin % is -93.99%. Medigen Vaccine Biologics' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Pretax Margin % is -93.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued. The current stock price of NT$46.35 is trading 33.8% below its estimated GF Value™ of NT$70.01. GuruFocus considers Medigen Vaccine Biologics to be Possible Value Trap.

Key valuation signals for ROCO:6547:

  • Pretax Margin %: -93.99%
  • GF Value™: NT$70.01 vs. price of NT$46.35 (33.8% below fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medigen Vaccine Biologics Business Description

Address 302 No. 68, Shengyi 3rd Road, Hsinchu County, Zhubei, TWN, 30261
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
67GF Score

Get the complete analysis for ROCO:6547

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$46.35
Price
NT$70.01
GF Value